David Hutton

The agreement settles Zeiss’s lawsuit against Topcon’s US-based subsidiaries that had been set to start this month in US federal court for the Northern District of California.

Trial will analyze efficacy, safety of AVD-104 versus avacincaptad pegol to treat GA

Under the terms of the agreement, Kiora Pharmaceuticals and Théa Open Innovation will develop and commercialize KIO-301 for the treatment of inherited retinal diseases in a deal valued at up to $301 million.

In a news release, the FDA noted these are copycat eye drop products that consumers can easily mistake for Bausch + Lomb’s Lumify brand eye drops, an over-the-counter product approved for redness relief.

According to the company, the deals from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024.

Massachusetts Eye and Ear researchers came up with a mobile app called All_Aboard, designed to be used along with mainstream GPS systems and focuses on improving micro-navigation.

A University of Houston professor found that the excitement over the results of LLR as a treatment option for patients with myopia may have come too soon, before its efficacy was confirmed.

The licensing deal includes upfront, development milestones, and sales royalties, with additional considerations throughout the term of the agreement.

According to the company, Eyconis Inc. is developed with a $150 million commitment from external investors.

Sanders is affiliated with the Retina Group of Washington (RGW) and PRISM Vision Group. He is the first African American and the first PRISM-affiliated physician to serve as president of the ASRS.

LambdaVision is leveraging the microgravity environment of the space station to develop higher-quality implants than is currently possible on Earth.

According to the company, ACDN-01 is the first-ever RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease. Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first half of 2024.

According to researchers at Johns Hopkins Children’s Center, AI-driven cameras take images of the back of the eye and require no eye drops can be used to close care gaps.

David Hutton of Ophthalmology Times talks with Adrienne Scott, MD, FASRS, about her part in a panel discussion detailing emerging therapies for AMD.

David Hutton of Ophthalmology Times talks with Sunir Garg, MD about his surgical video panel at this year's Retina Fellows Forum.

According to the company, favorable safety and tolerability profiles were observed with the first 2 SPVN06 doses across 6 patients. The exploration of SPVN06 in geographic geographic atrophy is set to begin in 2024.

According to the companies, the deal also includes Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams. Coherus will now focus on its oncology business.

The combined organization will support all aspects of ophthalmic clinical research, from front of the eye to back of the eye, leveraging an even larger team of experts with centuries of collective experience in ophthalmology.

According to the company, ABBV-RGX-314 continues to be well tolerated in over 100 patients from three dose levels with no drug-related serious adverse events. The new data was presented at the Hawaiian Eye and Retina meeting in Maui, by John Pitcher, MD, and includes 6-month results from two additional dose level 3 cohorts.

Allen Ho, MD, FACS, FASRS, will make a presentation at the meeting, to be held virtually on February 3.

Ophthalmology community continues to rally against efforts to expand the scope of optometrists in multiple states.

TRS01 ophthalmic solution is targeted for the treatment of non-infectious uveitis, including uveitic glaucoma.

According to the Advanced Research Projects Agency for Health, its program aims to transplant human eyes and reestablish visual connection to the brain.

NIDEK Co. Ltd. has made a financial donation to Orbis International to support Orbis’s artificial intelligence (AI)-based screening services in Vietnam.

According to an American Academy of Ophthalmology news release, Edmond’s priorities during her term include addressing physician and staff shortages and protecting patient safety at a time when nonphysicians are trying to expand their scope of practice into eye surgery.

Company presenting data from the Phase II AAVIATE trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration January 16 at the Hawaiian Eye and Retina 2024 Meeting.

According to a study by Johns Hopkins Children’s Center researchers, AI-driven cameras that take images of the back of the eye and require no eye drops can be used to close care gaps.

According to the company, EYP-1901 is an investigational sustained delivery therapy containing vorolanib, a selective tyrosine kinase inhibitor formulated in bioerodible Durasert E.

According to the company, all three patients treated for two years or more have remained free of symptoms and disease progression while taking gildeuretinol.

eSight’s medical equipment enhances vision for individuals with over 20 distinct ocular disorders, frequently enabling users to attain 20/20 vision. The Consumer Electronics Show runs January 9-12 in Las Vegas.